Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
NCT04924647Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in Rosai-Dorfman disease (RDD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Event-free survival at 5 years. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
Rosai-Dorfman disease (RDD)
Beyond the preview
Go deeper on NCT04924647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924647.